New York, NY -- (SBWIRE) -- 12/20/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Gevo, Inc (NASDAQ:GEVO), GT Advanced Technologies Inc (NASDAQ:GTAT), Credit Suisse AG - VelocityShares Daily 2x VIX Short Term ETN (NASDAQ:TVIX), Orexigen Therapeutics, Inc (NASDAQ:OREX)
Gevo, Inc (NASDAQ:GEVO) showed a volume of 2.57 million shares by the end of last trade whereas the average volume of the stock remained 1.90 million shares. The stock opened the session at $1.20 but then moved to $1.28. At that price, the stock showed a positive performance of 9.40%. Gevo, Inc., is a renewable chemicals and advanced biofuels company. The Company is focused on the development and commercialization of alternatives to petroleum-based products. The Company operates in two segments: Gevo, Inc. Segment and Gevo Development/Agri-Energy Segment. Gevo, Inc. Segment is responsible for all research and development activities related to the future production of isobutanol, maintaining and protecting its intellectual property portfolio, developing future markets for its isobutanol and providing corporate oversight services. I
Will GEVO Continue To Move Higher? Find Out Here
GT Advanced Technologies Inc (NASDAQ:GTAT) opened the session at $8.44 and closed the session at $8.54. The stock showed a positive performance of 1.59% in previous trading session. Traded with volume of 2.52 million shares in the prior session and the average volume of the stock remained 6.21 million shares. GT Advanced Technologies Inc. is diversified technology company with crystal growth equipment and solutions for the global solar, light emitting diode (LED) and electronics industries. The Company operates in three segments: its polysilicon business, its photovoltaic (PV), business and its sapphire business. The Company's principal products are Silicon Deposition Reactors (SDR) and related equipment used to produce polysilicon,
For How Long GTAT will fight for Profitability? Read This Trend Analysis report
Credit Suisse AG - VelocityShares Daily 2x VIX Short Term ETN (NASDAQ:TVIX) opened the session at 8.15 and closed the session at $8.12. The stock showed a positive performance of 1.25% in previous trading session. Traded with volume of 2.47 million shares in the prior session and the average volume of the stock remained 3.23 million shares. The beta of the stock remained -8.26.
Why Should Investors Buy TVIX After The Recent Gain? Just Go Here and Find Out
Orexigen Therapeutics, Inc (NASDAQ:OREX) the stock decreased -1.28% and finished the session at $5.39. Traded with volume of 2.45 million shares in the prior session and the average volume of the stock remained 2.90 million shares. The beta of the stock remained 2.14. Orexigen Therapeutics, Inc. develops drug treatments for obesity and related disorders. Orexigen Therapeutics, Inc. develops and commercializes combinations of currently available drugs that are designed to achieve and sustain weight loss by enhancing satiety, diminishing appetite, improving energy expenditure and minimizing the body's efforts to compensate for weight loss.
Will OREX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)